Vimta Labs Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹90Cr
- +23.3% YoY
- +5.9% QoQ
- Net profit
- ₹22Cr
- +144.4% YoY
- +46.7% QoQ
- Margin
- 37%
- +6 pp YoY
- +2 pp QoQ
Guidance rank: #18 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Based on Vimta Labs Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY25 Revenue from Operations: ₹899 Mn. Q3 FY25 EBITDA: ₹343 Mn, a 39.4% year-on-year (YoY) increase.
From Vimta Labs Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY25 Revenue from Operations: ₹899 Mn
- Q3 FY24 Revenue from Operations: ₹746 Mn
- Year-on-Year (YoY) Revenue Growth: 21.1% (from Q3 FY24 to Q3 FY25)
- Total Income Q3 FY25: ₹911 Mn (including other income)
- EBITDA Q3 FY25: ₹343 Mn with a margin of 37.6% (39.4% YoY growth)
- PAT Q3 FY25: ₹175 Mn with a margin of 19.2% (43.0% YoY growth)
2 more points from Vimta Labs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Q3 FY25 Capex: Rs 657 Mn (Page 6)
- 9M FY25 Capex: Rs 958 Mn (Page 7)
- Infrastructure growth over years shows increase in facility size from 500 ft² in 1984 to 600,000+ ft² in 2024 (Page 15), indicating ongoing expansions.
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Vimta Labs Ltd said on order book & pipeline — free account, 30 seconds.
Vimta Labs Ltd — Quarterly revenue & net profit
Vimta Labs Ltd Q3 FY25 results — key figures
| ₹ Cr | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 90 | 73 | +23.3% | 85 | +5.9% |
| Operating profit (EBITDA) | 33 | 23 | +43.5% | 30 | +10% |
| Operating margin | 37% | 31% | +6 pp | 35% | +2 pp |
| Profit before tax | 28 | 13 | +115.4% | 20 | +40% |
| Net profit (PAT) | 22 | 9 | +144.4% | 15 | +46.7% |
| EPS (₹) | 4.84 | 2.14 | +126.2% | 3.44 | +40.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹112 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Vimta Labs's management said in earlier quarters
Others in Healthcare Services this season
- 3B Blackbio (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Dr Lal Pathlabs (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
- Thyrocare Technologies (Q3 FY25)
Franchise revenue grew 24% YoY, partnerships business grew 23% YoY, and radiology business increased 13% YoY. Key concall takeaways from Thyrocare Technologies…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Vimta Labs Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vimta Labs Ltd Q3 FY25 results?
Q3 FY25 Revenue from Operations: ₹899 Mn. Q3 FY25 EBITDA: ₹343 Mn, a 39.4% year-on-year (YoY) increase.
What is Vimta Labs Ltd share price analysis?
Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 33.4 with a market cap of ₹2,696 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vimta Labs Ltd planning capital expenditure?
Q3 FY25 Capex: Rs 657 Mn (Page 6) - 9M FY25 Capex: Rs 958 Mn (Page 7)
Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
